Drugs / 188-0551
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04080206 | Apr 2020 → Jan 2021 | psoriasis | Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03065556 | Jan → Jul 2017 | psoriasis | Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03759197 | Nov 2018 → Aug 2019 | psoriasis | Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03731052 | Oct 2018 → Dec 2019 | psoriasis | Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 188-0551 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04080206 ↗ |
| Route | Topical | “188-0551 Solution applied topically twice daily” NCT03065556 ↗ |